173 related articles for article (PubMed ID: 28589759)
21. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
Kvasnicka HM; Thiele J
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612
[TBL] [Abstract][Full Text] [Related]
22. A clinical update in polycythemia vera and essential thrombocythemia.
Tefferi A; Solberg LA; Silverstein MN
Am J Med; 2000 Aug; 109(2):141-9. PubMed ID: 10967156
[TBL] [Abstract][Full Text] [Related]
23. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent.
Higuchi T; Okada S; Mori H; Niikura H; Omine M; Terada H
Cancer; 1995 Jan; 75(2):471-7. PubMed ID: 7812918
[TBL] [Abstract][Full Text] [Related]
24. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies.
Georgii A; Buhr T; Buesche G; Kreft A; Choritz H
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():15-29. PubMed ID: 8951769
[TBL] [Abstract][Full Text] [Related]
25. MPN blast phase: clinical challenge and assessing response.
Mesa RA; Tibes R
Leuk Res; 2012 Dec; 36(12):1496-7. PubMed ID: 22999527
[No Abstract] [Full Text] [Related]
26. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
Krahling T; Balassa K; Kiss KP; Bors A; Batai A; Halm G; Egyed M; Fekete S; Remenyi P; Masszi T; Tordai A; Andrikovics H
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):98-104. PubMed ID: 26487696
[TBL] [Abstract][Full Text] [Related]
27. Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.
Tallarico M; Odenike O
Curr Hematol Malig Rep; 2015 Jun; 10(2):112-7. PubMed ID: 25893311
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
Moulard O; Mehta J; Fryzek J; Olivares R; Iqbal U; Mesa RA
Eur J Haematol; 2014 Apr; 92(4):289-97. PubMed ID: 24372927
[TBL] [Abstract][Full Text] [Related]
29. Assessing disease burden in patients with classic MPNs.
Geyer H; Mesa RA
Best Pract Res Clin Haematol; 2014 Jun; 27(2):107-19. PubMed ID: 25189722
[TBL] [Abstract][Full Text] [Related]
30. How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
Titmarsh GJ; Duncombe AS; McMullin MF; O'Rorke M; Mesa R; De Vocht F; Horan S; Fritschi L; Clarke M; Anderson LA
Am J Hematol; 2014 Jun; 89(6):581-7. PubMed ID: 24971434
[TBL] [Abstract][Full Text] [Related]
31. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
Macavei I; Galatâr N
Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis.
Gill H; Leung AY; Chan CC; Lau JS; Chan C; Yip SF; Liu H; Kho B; Mak V; Lee HK; Lin SY; Lau CK; Kwong YL
Hematology; 2016 Jan; 21(1):10-8. PubMed ID: 26292161
[TBL] [Abstract][Full Text] [Related]
33. Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.
Geyer HL; Dueck AC; Scherber RM; Mesa RA
Mediators Inflamm; 2015; 2015():284706. PubMed ID: 26538823
[TBL] [Abstract][Full Text] [Related]
34. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.
Geyer HL; Scherber RM; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Vannucchi AM; Passamonti F; Samuelsson J; Birgegard G; Mesa RA
Blood; 2014 Jun; 123(24):3803-10. PubMed ID: 24553173
[TBL] [Abstract][Full Text] [Related]
35. Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.
Benton CB; Tanaka M; Wilson C; Pierce S; Zhou L; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2015 Apr; 39(4):419-23. PubMed ID: 25687833
[TBL] [Abstract][Full Text] [Related]
36. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
37. The role of genotypes that modify the toxicity of chemical mutagens in the risk for myeloproliferative neoplasms.
Gross-Davis CA; Heavner K; Frank AL; Newschaffer C; Klotz J; Santella RM; Burstyn I
Int J Environ Res Public Health; 2015 Feb; 12(3):2465-85. PubMed ID: 25719551
[TBL] [Abstract][Full Text] [Related]
38. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.
Abdulkarim K; Ridell B; Johansson P; Kutti J; Safai-Kutti S; Andréasson B
Eur J Haematol; 2011 Feb; 86(2):148-55. PubMed ID: 21059102
[TBL] [Abstract][Full Text] [Related]
39. Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.
Noor SJ; Tan W; Wilding GE; Ford LA; Barcos M; Sait SN; Block AW; Thompson JE; Wang ES; Wetzler M
Leuk Res; 2011 May; 35(5):608-13. PubMed ID: 20727590
[TBL] [Abstract][Full Text] [Related]
40. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]